Ferring B.V.

The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.

A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. Moreover, the inhibitor lessens deleterious effects associated with other IL-6 inhibitors such as lowering neutrophil counts, platelet counts and levels of C-reactive protein.

Described herein are mucoadhesive pharmaceutical compositions of corticosteroids, as well as methods of making such pharmaceutical compositions, and therapeutic methods using them. The compositions typically comprise a corticosteroid in a mucoadhesive system, wherein the mucoadhesive system comprises a rheology-modifying agent and a vehicle for the corticosteroid. The compositions are particularly useful for treating inflammatory conditions of the esophagus, such as eosinophilic esophagitis, or inflammatory bowel disease.

Methods using and compositions including FSH for use in the treatment of infertility are described, wherein the dose is selected based on the patient's age to optimise cumulative efficiency and/or reduce OHSS risk.

A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.

The present invention relates to crystalline forms of carbetocin, a method of their manufacture, and pharmaceutical compositions thereof.

The present invention relates to a device ( 60 ) for manufacturing pharmaceutical compositions, comprising: a support ( 62 ); a mixing container ( 16 ); a plurality of reservoirs ( 18, 20 ) containing starting materials for the composition of a medicament; at least one dispensing device ( 64, 66 ) that is designed to dispense an amount of a starting material into the mixing container, wherein the dispensing device is assembled, or is designed to be assembled, with a reservoir; a stirring device ( 68 ) that is able to stir the mixing container and/or the contents of the mixing container; and an electronic module ( 74 ) for controlling the at least one dispensing device.

Microbiota restoration therapy compositions and methods for making and using microbiota restoration therapy compositions are disclosed. One example method is a method for enhancing the immune system of a patient. The method may include administering a microbiota restoration therapy composition to a patient with a primary condition. The method may also include administering a treatment for the primary condition to the patient. The treatment may be designed to treat the primary condition.

The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.

A free-flowing solid pharmaceutical formulation comprising one or more active ingredients and a blend comprising sorbitol and liquid paraffin, a package containing the formulation, a process for the manufacture of the formulation and the use of the blend in the formulation.